PHIO
Price
$2.25
Change
-$0.00 (-0.00%)
Updated
Aug 8 closing price
Capitalization
10.8M
SLRX
Price
$0.50
Change
-$0.06 (-10.71%)
Updated
Aug 8 closing price
Capitalization
3.82M
Interact to see
Advertisement

PHIO vs SLRX

Header iconPHIO vs SLRX Comparison
Open Charts PHIO vs SLRXBanner chart's image
Phio Pharmaceuticals
Price$2.25
Change-$0.00 (-0.00%)
Volume$170.99K
Capitalization10.8M
Salarius Pharmaceuticals
Price$0.50
Change-$0.06 (-10.71%)
Volume$754.53K
Capitalization3.82M
PHIO vs SLRX Comparison Chart in %
Loading...
PHIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SLRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
PHIO vs. SLRX commentary
Aug 11, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PHIO is a Hold and SLRX is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 11, 2025
Stock price -- (PHIO: $2.25 vs. SLRX: $0.50)
Brand notoriety: PHIO and SLRX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: PHIO: 12% vs. SLRX: 18%
Market capitalization -- PHIO: $10.8M vs. SLRX: $3.82M
PHIO [@Biotechnology] is valued at $10.8M. SLRX’s [@Biotechnology] market capitalization is $3.82M. The market cap for tickers in the [@Biotechnology] industry ranges from $93.98B to $0. The average market capitalization across the [@Biotechnology] industry is $1.78B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PHIO’s FA Score shows that 0 FA rating(s) are green whileSLRX’s FA Score has 0 green FA rating(s).

  • PHIO’s FA Score: 0 green, 5 red.
  • SLRX’s FA Score: 0 green, 5 red.
According to our system of comparison, PHIO is a better buy in the long-term than SLRX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PHIO’s TA Score shows that 3 TA indicator(s) are bullish while SLRX’s TA Score has 2 bullish TA indicator(s).

  • PHIO’s TA Score: 3 bullish, 6 bearish.
  • SLRX’s TA Score: 2 bullish, 8 bearish.
According to our system of comparison, PHIO is a better buy in the short-term than SLRX.

Price Growth

PHIO (@Biotechnology) experienced а -3.43% price change this week, while SLRX (@Biotechnology) price change was -20.63% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +22.35%. For the same industry, the average monthly price growth was +31.87%, and the average quarterly price growth was +19.42%.

Industries' Descriptions

@Biotechnology (+22.35% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PHIO($10.8M) has a higher market cap than SLRX($3.82M). PHIO YTD gains are higher at: 25.000 vs. SLRX (-72.826). SLRX has higher annual earnings (EBITDA): -5.68M vs. PHIO (-7.05M). PHIO has more cash in the bank: 13.3M vs. SLRX (1.8M). PHIO has less debt than SLRX: PHIO (0) vs SLRX (112K). PHIO (0) and SLRX (0) have equivalent revenues.
PHIOSLRXPHIO / SLRX
Capitalization10.8M3.82M283%
EBITDA-7.05M-5.68M124%
Gain YTD25.000-72.826-34%
P/E Ratio0.01N/A-
Revenue00-
Total Cash13.3M1.8M740%
Total Debt0112K-
FUNDAMENTALS RATINGS
PHIO vs SLRX: Fundamental Ratings
PHIO
SLRX
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
57
Fair valued
88
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
98100
PRICE GROWTH RATING
1..100
5196
P/E GROWTH RATING
1..100
65100
SEASONALITY SCORE
1..100
550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PHIO's Valuation (57) in the Biotechnology industry is in the same range as SLRX (88) in the null industry. This means that PHIO’s stock grew similarly to SLRX’s over the last 12 months.

PHIO's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as SLRX (100) in the null industry. This means that PHIO’s stock grew similarly to SLRX’s over the last 12 months.

PHIO's SMR Rating (98) in the Biotechnology industry is in the same range as SLRX (100) in the null industry. This means that PHIO’s stock grew similarly to SLRX’s over the last 12 months.

PHIO's Price Growth Rating (51) in the Biotechnology industry is somewhat better than the same rating for SLRX (96) in the null industry. This means that PHIO’s stock grew somewhat faster than SLRX’s over the last 12 months.

PHIO's P/E Growth Rating (65) in the Biotechnology industry is somewhat better than the same rating for SLRX (100) in the null industry. This means that PHIO’s stock grew somewhat faster than SLRX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
PHIOSLRX
RSI
ODDS (%)
N/A
Bearish Trend 4 days ago
84%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
81%
Bullish Trend 4 days ago
83%
Momentum
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
90%
MACD
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
90%
Advances
ODDS (%)
Bullish Trend 20 days ago
82%
Bullish Trend 22 days ago
81%
Declines
ODDS (%)
Bearish Trend 5 days ago
90%
Bearish Trend 6 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
90%
Aroon
ODDS (%)
Bullish Trend 4 days ago
79%
Bearish Trend 4 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
PHIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SLRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
OKYO3.270.11
+3.48%
OKYO Pharma Limited
GLAD27.330.22
+0.81%
Gladstone Capital Corp
AWR75.65-0.40
-0.53%
American States Water Company
CHD90.92-1.71
-1.85%
Church & Dwight Co
CLIK0.33-0.04
-9.76%
Click Holdings Ltd

PHIO and

Correlation & Price change

A.I.dvisor indicates that over the last year, PHIO has been closely correlated with RIGL. These tickers have moved in lockstep 84% of the time. This A.I.-generated data suggests there is a high statistical probability that if PHIO jumps, then RIGL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PHIO
1D Price
Change %
PHIO100%
N/A
RIGL - PHIO
84%
Closely correlated
+4.14%
CLNN - PHIO
83%
Closely correlated
+0.27%
DARE - PHIO
81%
Closely correlated
-5.88%
IMRN - PHIO
71%
Closely correlated
+5.56%
TPST - PHIO
51%
Loosely correlated
+4.69%
More

SLRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, SLRX has been loosely correlated with MBIO. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if SLRX jumps, then MBIO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SLRX
1D Price
Change %
SLRX100%
-10.07%
MBIO - SLRX
64%
Loosely correlated
+9.21%
AMLX - SLRX
54%
Loosely correlated
-2.55%
PHIO - SLRX
40%
Loosely correlated
N/A
ATRA - SLRX
39%
Loosely correlated
-0.05%
AZTR - SLRX
36%
Loosely correlated
-2.32%
More